Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 320,000 shares for a total cost of HKD 579,000 on November 3, 2025, indicating a strategic move to enhance shareholder value [1] Company Summary - Hema Medical's stock closed at HKD 1.82 on November 3, 2025, remaining unchanged from the previous trading day, with a trading volume of 1.19 million shares and a turnover of HKD 2.1346 million [1] - The company has a market capitalization of HKD 2.26 billion, ranking 15th in the medical services sector [1] Financial Metrics - Return on Equity (ROE) stands at -6.36%, significantly lower than the industry average of 0.02%, ranking 39th out of 60 [1] - The circulating market value in Hong Kong is HKD 22.6 billion, compared to the industry average of HKD 78.25 billion, ranking 15th out of 60 [1] - Revenue is reported at HKD 19.35 billion, below the industry average of HKD 38.32 billion, also ranking 15th out of 60 [1] - Net profit margin is at 5.95%, contrasting sharply with the industry average of -843.36%, ranking 25th out of 60 [1] - Gross profit margin is 31.12%, lower than the industry average of 39.76%, ranking 28th out of 60 [1] - Debt ratio is 29.8%, significantly better than the industry average of 74.15%, ranking 21st out of 60 [1]

希玛医疗(03309)发布公告，于2025年11月3日斥资57.9万港元回购32万股。 ...

格隆汇11月3日丨希玛医疗(03309.HK)发布公告，2025年11月3日耗资57.87万港元回购32万股，回购价 格每股1.79-1.82港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | | | | | FF305 | | --- | --- | --- | --- | --- | | 186,000 | 0.0148 % | HKD | 2.64 | | | 820,000 | 0.0653 % | HKD | 2.3011 | | | 1,000,000 | 0.0796 % | HKD | 2.0394 | | | 500,000 | 0.0398 % | HKD | 1.8679 | | | 490,000 | 0.039 % | HKD | 1.8986 | | | 320,000 | 0.0255 % | HKD | 2.1199 | | | | 變動日期 | 2024年9月2日 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 4). | 已購回但沒有註銷的股份 | | 500,000 | 0.0398 % | HKD | 1.8679 | | | 變動日期 | 2024年9月9日 | | | | | | 5 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 希瑪醫療控股有限公司 呈交日期: 2025年10月31日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.1 | HKD | | 800,000,000 | 本月底法定/註 ...

Core Insights - A total of 30 companies conducted share buybacks on October 30, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2] - The total buyback amount for China Feihe was 50.23 million yuan, with 12 million shares repurchased, representing a significant investment in its own stock [1][2] Summary by Company - **China Feihe (06186)**: Repurchased 12 million shares for 50.23 million yuan; cumulative buybacks for the year reached 30.95 million shares, accounting for 0.341% of total share capital [2] - **China Petroleum & Chemical Corporation (00386)**: Repurchased 4.78 million shares for 19.72 million yuan; cumulative buybacks for the year reached 102 million shares, accounting for 0.080% of total share capital [2] - **Stone Four Pharmaceutical Group (02005)**: Repurchased 5 million shares for 15.41 million yuan; cumulative buybacks for the year reached 44.20 million shares, accounting for 1.498% of total share capital [2] - **Lianlian Digital (02598)**: Repurchased 1.38 million shares for 11.31 million yuan; cumulative buybacks for the year reached 4.45 million shares, accounting for 1.065% of total share capital [2] - **Gushengtang (02273)**: Repurchased 290,100 shares for 8.33 million yuan; cumulative buybacks for the year reached 5.88 million shares, accounting for 2.482% of total share capital [2] - **Lianyi Technology-W (09959)**: Repurchased 2.3 million shares for 7.42 million yuan; cumulative buybacks for the year reached 80.04 million shares, accounting for 3.746% of total share capital [2] - **Mongolian Dairy (02319)**: Repurchased 400,000 shares for 5.70 million yuan; cumulative buybacks for the year reached 22.42 million shares, accounting for 0.573% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: Repurchased 280,000 shares for 4.21 million yuan; cumulative buybacks for the year reached 7.84 million shares, accounting for 9.216% of total share capital [2] - **Other Companies**: Various other companies also participated in buybacks, with amounts ranging from 4.51 million yuan to 6 million yuan, and share counts varying significantly [2]

Group 1 - The company, Hema Medical (03309), repurchased 200,000 shares at a cost of approximately HKD 353,600 on October 30, 2025 [1]

Core Viewpoint - The company, 希玛医疗 (03309), announced a share buyback plan, indicating a commitment to enhancing shareholder value through the repurchase of shares [1] Group 1 - The company will spend approximately HKD 353,600 to repurchase 200,000 shares [1]

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 200,000 shares at a cost of HKD 374,000 on October 30 [1] Group 1 - The company executed a buyback program, indicating a potential strategy to enhance shareholder value [1] - The total expenditure for the buyback was HKD 374,000, reflecting the company's commitment to returning capital to shareholders [1] - The number of shares repurchased was 200,000, which may influence the stock's liquidity and market perception [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年10月30日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事 ...